ClinicalTrials.gg
CompletedNCT01250210Updated Jul 5, 2018Results posted

Evaluation of Pharmacodynamic Effects on Ovulation and Cycle Control

A Phase 2 interventional study of levonorgestrel and ethinyl estradiol in Ovulation Suppression, sponsored by Agile Therapeutics. Completed at 11 sites in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-07-05.

Sponsored by Agile Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

Evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs).

Read the detailed description

The primary objective was to evaluate the adequacy of ovulation suppression, cycle control, and safety of three transdermal contraceptive delivery systems (TCDSs) containing 2 different doses of levonorgestrel (LNG) and 3 different doses of ethinyl estradiol (EE) during 3 consecutive cycles of administration of each treatment.

02

Conditions studied

  • Ovulation Suppression

Keywords

  • contraception
  • pregnancy prevention
03

In context

Lead sponsor

Agile Therapeutics is the lead sponsor of 8 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult women, ages 18-45.
  2. Cycles with a usual duration between 21 and 35 days and an individual variation of +/ 3 days.
  3. Normotensive (blood pressure \< 140/90 mm Hg at rest) at screening and randomization visits (Visits 1 and 2).
  4. Willing to use a non-hormonal method of for the entire duration of the study, or
  5. Have already undergone previous bilateral tubal ligation OR vasectomized partner OR not at risk of pregnancy.
  6. Willing to refrain from excessive use of alcohol during the entire duration of the study.
  7. Willing to give to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. History of significant medical illness or seizures.
  2. Positive or C antibody or positive (HIV) antibody.
  3. Known or suspected pregnancy.
  4. A recent abnormal cervical smear - low-grade squamous intraepithelial lesion (SIL) or higher in the Bethesda System - which has not been resolved or treated.
  5. Any disorder that contraindicates the use of i.e., history of heart attack and stroke, blood clots in the legs, lungs or eyes, history of blood clots in the deep veins of the legs, known or suspected breast cancer, hepatitis or yellowing of the whites of the eyes or the skin (jaundice) during pregnancy or during previous use of hormonal contraceptives, headaches with neurological symptoms, disease of heart valves with complications.
  6. Uncontrolled thyroid disorder.
  7. History of or existing thromboembolic disorder, vascular disease, cerebral vascular, or coronary artery disease.
  8. Undiagnosed abnormal genital bleeding.
  9. Known or suspected breast carcinoma, endometrial carcinoma, or estrogen-dependent neoplasia.
  10. History or presence of dermal in response to topical application.
  11. Use of an injectable hormonal contraceptive (e.g. Depo-Provera®) within 6 months prior to Day 1.
  12. Use of a contraceptive implant (e.g. Implanon® or Jadelle®) or hormone-medicated intrauterine device within 2 months (60 days) prior to Day 1.
  13. Use of OCs or other sex steroid hormones within 60 days prior to Day 1.
  14. Women who are breast-feeding or are within 2 months of stopping breast-feeding.
  15. Status post-partum or post-abortion within a period of 2 months prior to Day 1.
  16. Chronic use of any medication that might interfere with the metabolism of hormone contraceptives (e.g., rifampin, barbiturates, phenytoin, primidone, topiramate, carbamazepine, phenylbutazone, ritonavir, modafinil, St John's Wort etc.) or use within the past 3 months prior to Day 1.
  17. Administration of drug within 30 days prior to Day 1.
  18. A history (within prior 12 months) of drug or alcohol abuse.
  19. Women who smoke more than 4-5 cigarettes daily.
  20. History of skin sensitivity to adhesives.
  21. Use of over-the-counter medications or herbals that might interfere with the metabolism of hormone contraceptives within 3 days prior to wearing the first patch.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
123 participants (actual)

Study arms

  • Experimental
    AG200-15

    Drug intervention with levonorgestrel and ethinyl estradiol : AG200-15 a transdermal contraceptive system containing 2.60 mg of levonorgestrel and 2.30 mg of ethinyl estradiol.

    Drug: levonorgestrel and ethinyl estradiol

  • Experimental
    AG200

    Drug intervention with levonorgestrel and ethinyl estradiol: AG200 a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.92 of ethinyl estradiol.

    Drug: levonorgestrel and ethinyl estradiol

  • Experimental
    AG200LE

    Drug intervention with levonorgestrel and ethinyl estradiol: AG200LE a transdermal contraceptive system containing 2.17 mg of levonorgestrel and 1.28 mg of ethinyl estradiol.

    Drug: levonorgestrel and ethinyl estradiol

Interventions

  • Druglevonorgestrel and ethinyl estradiol

    Drug pages: Levonorgestrel · Ethinyl Estradiol

    pregnancy prevention

    Also known as: contraception, hormonal contraception, transdermal

06

What researchers measure

Primary outcomes

  1. Ovulation Suppression in Three Treatment Groups Over 3 Cycles

    Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are: Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points. Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points. Perfect compliance: If no patch has been off \>1 day and no more than 1 day has elapsed between patch changes. Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.

    Time frame: 3 months

  2. Cycle Control

    The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.

    Time frame: 3 months

07

Results

Posted Jul 5, 2018

Participant flow

Planned enrollment included: approximately 30 subjects in the AG200LE treatment group, 30 subjects in the AG200 treatment group and 20 to 30 subjects in the AG200 15 treatment group. Actual enrollment included: 45 subjects in the AG200 treatment group; 45 subjects in the AG200LE treatment group; and 33 subjects in the AG200-15 treatment group.

Participant flow — Overall Study
MilestoneAG200LE Transdermal Contraceptive Delivery SystemAG200 Transdermal Contraceptive Delivery SystemAG200-15 Transdermal Contraceptive System
Started454533
Completed414125
Not completed448

Outcome measures

PrimaryOvulation Suppression in Three Treatment Groups Over 3 Cycles

Ovulation suppression measured by possible ovulation. Possible ovulation is defined as cycles with greatest progesterone level ≥4.7 ng/mL across Cycles 1-3 combined for each Arm/Group. The following four primary analysis datasets are: Intent-to-treat (ITT): At least 1 study patch was applied and at least 1 progesterone measurement is available at 1 of the nominal data collection points. Complete progesterone: At least 1 study patch was applied and at least 3 progesterone measurements are available across any of the data collection points. Perfect compliance: If no patch has been off \>1 day and no more than 1 day has elapsed between patch changes. Verifiable compliance: is a cycle during which at least 1 study patch was applied and where LNG and EE measurements were available at each of the nominal data collection points of Days 8, 15, and 22, and all values were above the lower detection limit.

Time frame:
3 months
Reported as:
Number · %of cycles with possible ovulation
Ovulation Suppression in Three Treatment Groups Over 3 Cycles
%of cycles with possible ovulationAG200LEAG200AG200-15
ITT, perfect compliance36.520.711.5
Complete progesterone, perfect compliance36.920.711.7
ITT, verifiable compliance32.514.912.0
Complete progesterone, verifiable compliance32.514.912.0
PrimaryCycle Control

The incidence of breakthrough bleeding (BTB) and/or spotting (S) episodes in Cycle 3 for ITT cycles. A BTB/S episode was defined as any number of days with BTB and/or BTS preceded and followed by at least 2 bleeding-free days.

Time frame:
3 months
Reported as:
Mean · number of episodes
Cycle Control
number of episodesAG200LEAG200AG200-15
Cycle Control0.29 ± 0.460.29 ± 0.460.15 ± 0.36

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AG200LE0/43 (0%)0/43 (0%)19/43 (44.2%)
AG2000/44 (0%)0/44 (0%)29/44 (65.9%)
AG200-150/31 (0%)0/31 (0%)19/31 (61.3%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventAG200LEAG200AG200-15
Infections and infestationsInfections and infestations4/432/446/31
Reproductive system and breast disordersReproductive system and breast disorders3/436/446/31
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders4/436/446/31
Gastrointestinal disordersGastrointestinal disorders2/436/445/31
General disorders and administration site conditionsGeneral disorders2/435/445/31
Respiratory, thoracic and mediastinal disordersRespiratory, thoracic and mediastinal disorders5/436/444/31
Nervous system disordersNervous system disorders1/435/443/31
InvestigationsInvestigations2/433/441/31
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders0/433/441/31
Renal and urinary disordersRenal and urinary disorders1/430/442/31

Baseline characteristics

Safety Population

Age, Categorical
Age, Categorical(Participants)AG200LE Transdermal Contraceptive Delivery SystemAG200 Transdermal Contraceptive Delivery SystemAG200-15 Transdermal Contraceptive SystemTotal
<=18 years0000
Between 18 and 65 years434431118
>=65 years0000
Age, Continuous
Age, Continuous(years)AG200LE Transdermal Contraceptive Delivery SystemAG200 Transdermal Contraceptive Delivery SystemAG200-15 Transdermal Contraceptive SystemTotal
Mean31.7 ± 7.431 ± 6.932.1 ± 7.831.6 ± 7.3
Sex: Female, Male
Sex: Female, Male(Participants)AG200LE Transdermal Contraceptive Delivery SystemAG200 Transdermal Contraceptive Delivery SystemAG200-15 Transdermal Contraceptive SystemTotal
Female434431118
Male0000
Region of Enrollment
Region of Enrollment(Participants)AG200LE Transdermal Contraceptive Delivery SystemAG200 Transdermal Contraceptive Delivery SystemAG200-15 Transdermal Contraceptive SystemTotal
United States434431118
08

Study locations

11 sites
  • Tucson, Arizona 85712, United States
  • San Diego, California 92108, United States
  • Denver, Colorado 80218, United States
  • Pembroke Pines, Florida 33026, United States
  • Tampa, Florida 33607, United States
  • Sandy Springs, Georgia 30328, United States
  • Cary, North Carolina 27518, United States
  • Winston-Salem, North Carolina 27103, United States
  • Jenkintown, Pennsylvania 19046, United States
  • Philadelphia, Pennsylvania 19114, United States
  • Bristol, Tennessee 37620, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2018, 10 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2010
First posted
Nov 30, 2010
Start
Sep 2007
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Jul 5, 2018
Last update
Jul 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01250210
Lead sponsor
Agile Therapeutics
Responsible party
Sponsor
First posted
Nov 30, 2010
Start date
Sep 2007
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Jul 5, 2018
Last update
Jul 5, 2018

Study contacts

Elizabeth Garner, MD, MPH
study director · Agile Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Levonorgestrel · Ethinyl Estradiol

Start the discussion